Role of Natural Products in Developing Novel Anticancer Agents: A Perspective.
anti-cancer
chemotherapy
cytotoxicity
natural products
Journal
Chemistry & biodiversity
ISSN: 1612-1880
Titre abrégé: Chem Biodivers
Pays: Switzerland
ID NLM: 101197449
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
03
06
2022
accepted:
06
10
2022
pubmed:
9
11
2022
medline:
23
11
2022
entrez:
8
11
2022
Statut:
ppublish
Résumé
Cancer is a heterogeneous disease and is one of the significant health issues, especially in public health systems around the world. Natural products and their structural derivatives with outstanding chemical diversity have been investigated for potential anti-cancer agents. Many natural products revealing potential anti-cancer properties such as cytotoxicity, proliferation inhibition, induced apoptosis, retard metastasis, suppressing angiogenesis, and improved chemotherapy have been isolated from various plants and herbs. Several promising lead molecules have been identified recently; a few are in the clinical trial stage. This short communication summarises the role of natural products and their analogs in anti-cancer drug developments, especially plant, marine and microbial-based anti-cancer agents.
Identifiants
pubmed: 36347633
doi: 10.1002/cbdv.202200535
doi:
Substances chimiques
Biological Products
0
Antineoplastic Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e202200535Informations de copyright
© 2022 The Authors. Chemistry & Biodiversity published by Wiley-VHCA AG, Zurich, Switzerland.
Références
A. G. Atanasov, S. B. Zotchev, V. M. Dirsch, C. T. Supuran, ‘Natural products in drug discovery: advances and opportunities’, Nat. Rev. Drug Discovery 2021, 20, 200-216.
A. A. Siddiqui, F. Iram, S. Siddiqui, K. Sahu, ‘Role of natural products in drug discovery process’, Int. J. Drug Dev. Res. 2014, 6, 0-5.
M. Huang, J. J. Lu, J. Ding, ‘Natural products in cancer therapy: past, present and future’, Nat. Prod. Bioprospect. 2021, 11, 5-13.
D. A. Dias, S. Urban and U. Roessner, ‘A historical overview of natural products in drug discovery’, Metabolites. 2012, 16, 303-336.
G. Molinari, ‘Natural products in drug discovery: present status and perspectives’, Pharm. Biotechnol. 2009, 13-27.
G. M. Cragg, D. J. Newman, K. M. Snader, ‘Natural products in drug discovery and development’, J. Nat. Prod. 1997, 60, 52-60.
S. K. Ghosh, ‘Giovanni Battista Morgagni (1682-1771): father of pathologic anatomy and pioneer of modern medicine’, Anat. Sci. Int. 2017, 92, 305-312.
J. Dobson, ‘John Hunter's views on cancer’, Ann. R. Coll. Surg. Engl. 1959, 25, 176-181.
R. J. Papac, ‘Origins of cancer therapy’, Yale J. Biol. Med. 2001, 74, 391-398.
S. H. E. Kaufmann, ‘Paul Ehrlich: founder of chemotherapy’, Nat. Rev. Drug Discovery 2008, 7, 373.
N. N. Howlader, A. M. Noone, M. E. Krapcho, D. Miller, A. Brest, Y ME, J. Ruhl, Z. Tatalovich, A. Mariotto, D. R. Lewis, H. S. Chen, ‘SEER cancer statistics review, 1975-2016’, National Cancer Institute. 2019, 8, 1.
K. H. Pii, L. H. Schou, K. Piil, M. Jarden, ‘Current trends in patient and public involvement in cancer research: a systematic review’, Health Expect. 2019, 22, 3-20.
C. P. Wild, E. Weiderpass, and B. W. Stewart, ‘World Cancer Report 2020’, International Agency for Research on Cancer 2020.
S. Kehoe, and N. Bhatla, ‘FIGO Cancer Report 2021’, International Journal of Gynecology and Obstetrics 2021.
World Health Organization (2020) WHO report on cancer: setting priorities, investing wisely and providing care for all 2020.
G. M. Cragg, D. J. Newman, ‘Plants as a source of anti-cancer agents’, J. Ethnopharmacol. 2005, 100, 72-79.
A. L. Demain, P. Vaishnav, ‘Natural products for cancer chemotherapy’, Microb. Biotechnol. 2011, 4, 687-699.
J. Khazir, D. L. Riley, L. A. Pilcher, P. De-Maayer, B. A. Mir, ‘Anti-cancer agents from diverse natural sources’, Nat. Prod. Commun. 2014, 9 : 1934578X1400901130.
J. Sharifi-Rad, A. Ozleyen, T. B. Tumer, C. O. Adetunji, El. N. Omari, B. A. Taheri, A. Bouyahya, M. Martorell, C. N. Martins, W. Cho, ‘Natural products and synthetic analogs as a source of antitumor drugs’, Biomol. Eng. 2019, 1, 679.
M. J. Nirmala, A. Samundeeswari, P. D. Sankar, ‘Natural plant resources in anti-cancer therapy-A review’, Res. Plant Biol. 2011, 1, 01-14.
M. Gordaliza, ‘Natural products as leads to anti-cancer drugs’, Clin. Transl. Oncol. 2007, 9, 767-776.
G. M. Cragg, P. G. Grothaus, D. J. Newman, ‘Impact of natural products on developing new anti-cancer agents’, Chem. Rev. 2009, 109, 3012-3043.
D. J. Newman, G. M. Cragg, ‘Natural products as sources of new drugs from 1981 to 2014’, J. Nat. Prod. 2016, 25, 629-661.
S. Shukla, A. Mehta, ‘Anti-cancer potential of medicinal plants and their phytochemicals: a review’, Rev. Bras. Bot. 2015, 38,199-210.
W. Ramakrishna, A. Kumari, N. Rahman, P. Mandave, ‘Anticancer activities of plant secondary metabolites: Rice callus suspension culture as a new paradigm’, Ric. Sci. 2021, 28, 13-30.
A. Bishayee, G. Sethi, ‘Bioactive natural products in cancer prevention and therapy: Progress and promise’, Semin. Cancer Biol. 2016, 40, 1-3.
S. Arora, P. Narayan, C. L. Osgood, S. Wedam, T. M. Prowell, J. J. Gao, M. Shah, D. Krol, S. Wahby, M. Royce, S. Ghosh, ‘US FDA drug approvals for breast cancer: A decade in review’, Clin. Cancer Res. 2022, 28, 1072-1086.
D. J. Benjamin, A. Xu, M. P. Lythgoe, V. Prasad, ‘Cancer drug approvals that displaced existing standard-of-care therapies, 2016-2021’, JAMA Netw. 2022, 5, e222265-.
G. Velikova, L. J. Williams, S. Willis, ‘Correction to Lancet Oncol 2018’, Lancet Oncol. 2018, 19, 1516-1529.
T. Khan, M. Ali, A. Khan, P. Nisar, S. A. Jan, S. Afridi, Z. K. Shinwari, ‘Anti-cancer plants: A review of the active phytochemicals, applications in animal models, and regulatory aspects’, Biomol. Eng. 2019,10, 47.
O. M. Prakash, A. Kumar, P. Kumar, ‘Anti-cancer potential of plants and natural products’, Am. J. Pharmacol. Sci. 2013, 1, 104-115.
V. Walsh, J. Goodman, ‘From taxol to taxol®: The changing identities and ownership of an anti-cancer drug’, Med. Anthropol. 2002, 21, 307-336.
R. H. Mathijssen, W. J. Loos, J. Verweij, ‘Sparreboom A. Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan’, Curr. Cancer Drug Targets. 2002, 2, 103-123.
M. Khanavi, S. Pourmoslemi, B. Farahanikia, A. Hadjiakhoondi, S. N. Ostad, ‘Cytotoxicity of Vinca minor’, Pharm. Biol. 2010, 48, 96-100.
A. D. Kinghorn, E. J. De Blanco, D. M. Lucas, H. L. Rakotondraibe, J. Orjala, D. D. D. Soejarto, N. H. Oberlies, C. J. Pearce, M. C. Wani, B. R. Stockwell, J. E. Burdette, ‘Discovery of anti-cancer agents of diverse natural origin’, Anticancer Res. 2016, 36, 5623-5637.
A. Sri, ‘Pharmacological activity of vinca alkaloids’, Phytochemistry 2016, 27, 27-34.
I. Ojima, B. Lichtenthal, S. Lee, C. Wang, X. Wang, ‘Taxane anti-cancer agents: a patent perspective’, Expert Opin. Ther. Pat. 2016, 26, 1-20.
L. A. Amos, J. Löwe, ‘How Taxol® stabilizes microtubule structure’, Chem. Biol. 1999, 6, R65-69.
J. Khazir, B. A. Mir, L. Pilcher, D. L. Riley, ‘Role of plants in anti-cancer drug discovery’, Phytochem. Lett. 2014, 7, 173-181.
E. Solowey, M. Lichtenstein, S. Sallon, H. Paavilainen, E. Solowey, H. Lorberboum-Galski, ‘Evaluating medicinal plants for anti-cancer activity’, Sci. World J. 2014, 721402.
M. Greenwell, P. K. Rahman, ‘Medicinal plants: their use in anti-cancer treatment’, Int. J. Pharm. Sci. Res. 2015, 6, 4103-4112.
G. M. Cragg, J. M. Pezzuto, ‘Natural products as a vital source for the discovery of cancer chemotherapeutic and chemopreventive agents’ Med. Princ. Pract. 2016, 25, 41-59.
M. Gordaliza, ‘Natural products as leads to anti-cancer drugs’, Clin. Transl. Oncol. 2007, 9, 767-76.
S. Neidle, editor, ‘Cancer drug design and discovery’, Elsevier; 2011.
E. I. Frei, ‘The clinical use of actinomycin’, Cancer Chemother. Rep. 1974, 58, 49-54.
Z. Farhane, F. Bonnier, H. J. Byrne, ‘An in vitro study of the interaction of the chemotherapeutic drug Actinomycin D with lung cancer cell lines using Raman micro-spectroscopy’, J. Biophotonics. 2018, 11, e201700112.
M. Ishizuka, ‘Activity and toxicity of bleomysin’, J. Antibiot. 1967, 20, 15-24.
Z. J. Segerman, B. Roy, S. M. Hecht, ‘Characterisation of bleomycin-mediated cleavage of a hairpin DNA library’, Biochemistry. 2013, 52, 5315-5327.
S. T. Crooke, W. T. Bradner, ‘Mitomycin C: a review’, Cancer Treat. Rev. 1976, 3, 121-139.
T. F. Molinski, D. S. Dalisay, S. L. Lievens, J. P. Saludes, ‘Drug development from marine natural products’, Nat. Rev. Drug Discovery 2009, 1, 69-85.
T. N. Chinembiri, L. H. Du Plessis, M. Gerber, J. H. Hamman, J. Du Plessis, ‘Review of natural compounds for potential skin cancer treatment’, Molecules 2014, 19,11679-11721.
V. Ortega, J. Cortés, ‘Potential clinical applications of halichondrins in breast cancer and other neoplasms’, Breast Cancer (Dove Med Press) 2012, 4, 9-19.
M. Gallery, J. Zhang, D. P. Bradley, P. Brauer, D. Cvet, J. Estevam, H. Danaee, E. Greenfield, P. Li, M. Manfredi, H. K. Loke, ‘A monomethyl auristatin E-conjugated antibody to guanylyl cyclase C is cytotoxic to target-expressing cells in vitro and in vivo’, PLoS One 2018, 13, e0191046.
S. Indumathy, C. R. Dass, ‘Finding chemo: The search for marine-based pharmaceutical drugs active against cancer’, J. Pharm. Pharmacol. 2013, 65, 1280-1301.
L. G. Lin, H. Xie, H. L. Li, L. J. Tong, C. P. Tang, C. Q. Ke, Q. F. Liu, L. P. Lin, M. Y. Geng, H. Jiang, W. M. Zhao, ‘Naturally occurring homoisoflavonoids function as potent protein tyrosine kinase inhibitors by c-Src-based high-throughput screening’, J. Med. Chem. 2008, 5, 4419-4429.
‘DRUG BANK (2005) Drug Bank’, drug bank.
N. C. Kampan, M. T. Madondo, O. M. McNally, M. Quinn, M. Plebanski, ‘Paclitaxel and its evolving role in the management of ovarian cancer’, BioMed Res. Int. 2015, 1-21.
L. Zhu, L. Chen, ‘Progress in research on paclitaxel and tumor immunotherapy’ Cell. Mol. Biol. Lett. 2019, 24, 1-1.
K. J. Pienta, ‘Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer’, Semin. Oncol. 2001, 28, 3-7.
C. Obasaju, G. R. Hudes, ‘Paclitaxel and docetaxel in prostate cancer’, Hematol. Oncol. 2001, 15, 525-545.
A. Barve, A. Jain, H. Liu, Z. Zhao, K. Cheng, ‘Enzyme-responsive polymeric micelles of cabazitaxel for prostate cancer targeted therapy’, Acta Biomater. 2020, 113, 501-511.
L. F. Liu, S. D. Desai, L. I. TK, Y. Mao, M. E. Sun, S. P. SIM, ‘Mechanism of action of camptothecin’, Ann. N. Y. Acad. Sci. 2000, 922, 1-0.
N. Khaiwa, N. R. Maarouf, M. H. Darwish, D. W. Alhamad, A. Sebastian, M. Hamad, H. A. Omar, G. Orive, T. H. Al-Tel, ‘Camptothecin's journey from discovery to WHO Essential Medicine: Fifty years of promise’, Eur. J. Med. Chem. 2021, 223, 113639.
C. Kollmannsberger, K. Mross, A. Jakob, L. Kanz, C. Bokemeyer, ‘Topotecan-a novel topoisomerase I inhibitor: pharmacology and clinical experience’, Oncology. 1999, 56, 1-2.
Y. Xu, M. A. Villalona-Calero, ‘Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity’, Ann. Oncol. 2002, 13, 1841-1851.
E. R. El-Sayed, ‘Discovery of the anti-cancer drug vinblastine from the endophytic Alternaria alternata and yield improvement by gamma irradiation mutagenesis’, J. Appl. Microbiol. 2021, 131, 2886-2898.
A. S. Nugraha, Y. D. Damayanti, P. Wangchuk, P. A. Keller, ‘Anti-infective and anti-cancer properties of the Annona species: their ethnomedicinal uses, alkaloid diversity, and pharmacological activities’, Molecules. 2019, 24, 4419.
J. Škubník, V. S. Pavlíčková, T. Ruml, S. Rimpelová, ‘Vincristine in combination therapy of cancer: emerging trends in clinics’, Biology. 2021, 10, 849.
M. Moudi, R. Go, C. Y. Yien, M. azre, ‘Vinca alkaloids’, Int. J. Prev. Med. 2013, 11, 1231.
A. Capasso, ‘Vinorelbine in cancer therapy’, Curr. Drug Targets. 2012, 13, 1065-1071.
A. S. Choudhari, P. C. Mandave, M. Deshpande, P. Ranjekar, O. akash, ‘Phytochemicals in cancer treatment: From preclinical studies to clinical practice’, Front. Pharmacol. 2020, 10,1614.
A. Montecucco, F. Zanetta, G. Biamonti, ‘Molecular mechanisms of etoposide’, EXCLI journal 2015, 14, 95.
B. H. Long, ‘Mechanisms of action of teniposide (VM-26) and comparison with etoposide (VP-16)’, Semin. Oncol. 1992, 19, 3-19.
R. T. Dorr, ‘Bleomycin pharmacology: mechanism of action and resistance, and clinical pharmacokinetics’, Semin. Oncol. 1992, 19, 3-8.
G. Beziat, S. Tavitian, S. Bertoli, F. Huguet, L. Largeaud, I. Luquet, F. Vergez, J. B. Rieu, P. Bories, E. Delabesse, C. Récher, ‘Dactinomycin in acute myeloid leukemia with NPM1 mutations’, Eur. J. Haematol. 2020, 105, 302-307.
K. Renu, V. G. Abilash, S. Arunachalam, ‘Molecular mechanism of doxorubicin-induced cardiomyopathy-An update’, Eur. J. Pharmacol. 2018, 818, 241-253.
F. Yang, S. S. Teves, C. J. Kemp, S. Henikoff, ‘Doxorubicin, DNA torsion, and chromatin dynamics’, Biochim. Biophys. Acta Rev. Cancer 2014, 1845, 84-89.
M. Khasraw, R. Bell, C. Dang, ‘Epirubicin: is it like doxorubicin in breast cancer? A clinical review’, The Breast. 2012, 21, 142-149.
J. E. Frampton, ‘Mifamurtide’, Paediatr. Drugs 2010 12, 141-153.